Related Experiment Video
Updated: Aug 7, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
The macrolides: erythromycin, clarithromycin, and azithromycin
1Division of Infectious Diseases and Internal Medicine, Mayo Clinic Jacksonville, Florida, USA.
Abstract:
In addition to erythromycin, macrolides now available in the United States include azithromycin and clarithromycin. These two new macrolides are more chemically stable and better tolerated than erythromycin, and they have a broader antimicrobial spectrum than erythromycin against Mycobacterium avium complex (MAC), Haemophilus influenzae, nontuberculous mycobacteria, and Chlamydia trachomatis. All three macrolides have excellent activity against the atypical respiratory pathogens (C. pneumoniae and Mycoplasma species) and the Legionella species. Azithromycin and clarithromycin have pharmacokinetics that allow shorter dosing schedules because of prolonged tissue levels. Both azithromycin and clarithromycin are active agents for MAC prophylaxis in patients with late-stage acquired immunodeficiency syndrome (AIDS), although azithromycin may be the preferable agent because of fewer drug-drug interactions. Clarithromycin is the most active MAC antimicrobial agent and should be part of any drug regimen for treating active MAC disease in patients with or without AIDS. Although both azithromycin and clarithromycin are well tolerated by children, azithromycin has the advantage of shorter treatment regimens and improved tolerance, potentially improving compliance in the treatment of respiratory tract and skin or soft tissue infections. Intravenously administered azithromycin has been approved for treatment of adults with mild to moderate community-acquired pneumonia or pelvic inflammatory diseases. An area of concern is the increasing macrolide resistance that is being reported with some of the common pathogens, particularly Streptococcus pneumoniae, group A streptococci, and H. influenzae. The emergence of macrolide resistance with these common pathogens may limit the clinical usefulness of this class of antimicrobial agents in the future.
Insights
New macrolides like azithromycin and clarithromycin offer improved stability and broader spectrum against infections such as Mycobacterium avium complex (MAC). However, increasing macrolide resistance is a growing concern for future antimicrobial effectiveness.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Erythromycin has been a primary macrolide antibiotic, but newer agents offer distinct advantages.
- Azithromycin and clarithromycin represent advancements in macrolide antibiotic therapy.
Purpose of the Study:
- To compare the chemical stability, antimicrobial spectrum, pharmacokinetics, and clinical applications of azithromycin and clarithromycin versus erythromycin.
- To highlight the efficacy of azithromycin and clarithromycin in treating specific infections, including Mycobacterium avium complex (MAC) and atypical respiratory pathogens.
- To address the emerging issue of macrolide resistance and its potential impact on future treatment strategies.
Main Methods:
- Comparative analysis of chemical stability and antimicrobial spectrum.
- Pharmacokinetic profiling to assess dosing schedules and tissue penetration.
- Review of clinical data regarding efficacy in MAC prophylaxis and treatment, respiratory tract infections, skin/soft tissue infections, community-acquired pneumonia, and pelvic inflammatory diseases.
- Assessment of drug-drug interactions and pediatric tolerance.
Main Results:
- Azithromycin and clarithromycin exhibit enhanced chemical stability and broader antimicrobial activity compared to erythromycin, particularly against MAC, H. influenzae, and C. trachomatis.
- Both agents demonstrate excellent activity against atypical respiratory pathogens (C. pneumoniae, Mycoplasma) and Legionella species.
- Pharmacokinetics allow for shorter dosing schedules; both are effective for MAC prophylaxis in AIDS patients, with azithromycin preferred due to fewer interactions.
- Clarithromycin is crucial for treating active MAC disease; azithromycin offers advantages in pediatric compliance.
- Increasing macrolide resistance in S. pneumoniae, group A streptococci, and H. influenzae is a significant concern.
Conclusions:
- Azithromycin and clarithromycin are valuable macrolide antibiotics with improved profiles over erythromycin, offering effective treatment options for various infections.
- Their pharmacokinetic properties and efficacy in specific patient populations (e.g., AIDS, children) enhance therapeutic utility.
- The rising prevalence of macrolide resistance poses a threat to the long-term clinical effectiveness of this antibiotic class.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
10:49Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
Related Concept Videos
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis